Advances in USP22 Regulation of Signal Transduction Pathways in Tumors

LI Xuexue¹,WEI Xudong^1,2*, WANG Qianru³

(¹the First Clinical Medical College of Lanzhou University, Lanzhou 730000, China; ² Department of Otolaryngology, Head and Neck Surgery, Gansu Provincial People’s Hospital, 730000, China; ³ the First Clinical College of Gansu University of Traditional Chinese Medicine, 730000, China)

Abstract:

USP22, as one of the tumor stem cell markers, has been observed in several types of human cancers, suggesting that USP22 may be involved in various physiological and pathological processes and act as an oncogene in cancer progression. However, the mechanisms leading to the transcriptional activation of USP22, especially the mechanism by which USP22 mediates human tumor progression, remain unknown. Previous studies have shown that USP22 induces tumorigenesis mainly by regulating mitogen-stimulated activation in normal T cells and B cells or by viral infection. However, recent studies have shown that USP22 overexpression alone is not sufficient to induce tumorigenesis, and that USP22 is involved in tumor progression through the activation of tumor-associated signaling pathways, which provides new insights into the tumor mechanism and a new way of thinking about USP22-guided tumor therapeutic resistance. This article summarizes the relevant signaling pathways of USP22 involved in tumor progression, in order to find the molecular mechanism of USP22-mediated tumor development and the crosstalk between different signaling pathways on tumor progression, and provide new ideas for cancer treatment.

CSTR: 32200.14.cjcb.2024.02.0017